PharmCo III ApS: Financial statements 2024
CVR: 41103647
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
PharmCo III ApS (CVR 41103647) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -31,125 and a net result of DKK 13,877,698 compared with DKK 11,059,518 the year before. Equity in the 2024 report amounted to DKK 75,418,640. The solvency ratio was 88.8%.
- Revenue
- DKK 0
- Gross Profit
- DKK -31,125
- Profit/Loss
- DKK 13,877,698
- Equity
- DKK 75,418,640
- Total Assets
- DKK 84,969,696
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 0 | -31 t. | 13.9 mio. | 75.4 mio. | - |
| 2023 | - | -29 t. | 11.1 mio. | 61.4 mio. | - |
| 2022 | - | -27 t. | 12.1 mio. | 50.6 mio. | - |
| 2021 | 0 | -26 t. | 20.5 mio. | 39 mio. | - |
| 2020 | - | -35 t. | 18.6 mio. | 18.2 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
PharmCo III ApS has published its annual report for 2023. Gross profit came to DKK -29,175, and the net result was DKK 11,059,518.
About PharmCo III ApS
PharmCo III ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 2020. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Eli Wallin. The company is owned by Eli Wallin. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -33,000 and a net result of DKK 18,532,000 compared with DKK 13,877,698 the year before. Equity in the 2025 report amounted to DKK 100,696,000.